MedTrace Logo

Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

NCT02511002 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-04-08

No results posted yet for this study

Summary

Background:

\- Influenza is a common viral infection, but it can be deadly for some people. Researchers want to learn more about how the body fights this virus. They want to study this in people who have recently been infected with influenza. They hope this can help them create more effective influenza vaccines.

Objective:

\- To learn about long-term changes in the body s immune system after influenza infection.

Eligibility:

\- People who have completed a previous LID Clinical Studies Unit influenza challenge study or current or prior participation in an LID natural history study and are willing to have samples stored for future research.

Design:

* Eligible participants will be asked to visit the clinic every 3 months for 2 years.
* During each visit, participants will have blood drawn from an arm vein using a needle and a syringe and a nasal sample.
* Participants will have a medical history and physical exam and vital signs performed. This will include blood pressure, heart rate, breathing rate, temperature, weight, and finger-measured blood oxygen. They will answer questions about any medicines taken and possible recent illnesses.
* If participants have symptoms of influenza, they may have an additional sample taken from the nose.
* Participants will complete a health questionnaire once a month on a secure website. Participants may also give their responses over the telephone.

Conditions

  • Post Influenza

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Alison Han, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-17
Primary Completion
2027-05-12
Completion
2027-05-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511002 on ClinicalTrials.gov